Ibrahim Safra

Dr. Ibrahim Safra


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
RMRowan Mesilhy
Rowan Mesilhy
ISIbrahim Safra
Ibrahim Safra
SAShaikha Alnaimi
Shaikha Alnaimi
AAAlaa Awadullah Mohammed Ali
Alaa Awadullah Mohammed Ali
RTRayan Terkawi
Rayan Terkawi
AGAshraf Gad
Ashraf Gad
Background: Early-onset neonatal meningitis (EONM) is a rare but serious condition where antibiotics are often given for extended periods, even without a positive cerebrospinal fluid (CSF) culture. The reasons for this prolonged treatment are unknown. Methodology: This study, conducted at the Women’s Wellness and Research Center, Doha, retrospectively analyzed the determinants of prolonged antibiotic therapy among neonates with sterile CSF cultures during the first week of life, born during 2015 to 2018. Results: Of 315 neonates without confirmed meningitis, 96 (30.5%) received prolonged antibiotic therapy. These infants had significantly lower birth weights (2790 g vs. 3170 g) and gestational ages (36.7 weeks vs. 38.5 weeks). They were more likely to require respiratory support, appear ill, and have laboratory abnormalities, including neutropenia, positive blood cultures (36.5% vs. 0.9%), elevated C-reactive protein (CRP), and higher CSF protein. Multivariable analysis identified low Apgar scores (Adjusted Odds Ratio (aOR), 2.82), positive blood cultures (aOR, 118.48), traumatic lumbar puncture (LP) (aOR, 2.14), CRP levels ≥ 50 mg/L (aOR, 2.60), delayed LP (OR, 8.28), and elevated cerebrospinal fluid white cell counts (aOR, 5.47) as independent predictors of prolonged antibiotic use. Conclusions: Prolonged antibiotic use in neonates with sterile CSF cultures and suspected EONS is common and may be driven by certain clinical and laboratory indicators of illness severity and inflammation. Identifying these predictors can support risk-stratified treatment decisions, promoting safer antimicrobial stewardship.

Verified
Journal Article
Open access
PDF file
SAShaikha Alnaimi
Shaikha Alnaimi
SAShimaa Aboelbaha
Shimaa Aboelbaha
ISIbrahim Safra
Ibrahim Safra
MAMai AlQubaisi
Mai AlQubaisi
FAFouad Fawzy Ghanem A. Abounahia
Fouad Fawzy Ghanem A. Abounahia
Nader Al-DewikNader Al-Dewik
Nader Al-Dewik
The pharmacologic management of patent ductus arteriosus (PDA) presents a challenge to clinicians due to the interindividual variability in drug response to available medications. There is evidence that CYP2C9 is associated with the response to PDA treatment; however, no data from the Middle East is available. This study aimed to investigate the association between CYP2C8 and CYP2C9 genetic polymorphisms and response to ibuprofen or indomethacin in neonates with PDA. We conducted a retrospective cohort study of neonates with a gestational age < 32 weeks and birthweight < 1500 g with PDA between 2019 and 2023. Eligible neonates were those diagnosed with PDA and treated with at least one course of ibuprofen or indomethacin. Genotyping was performed to identify four single-nucleotide polymorphisms (SNPs), namely CYP2C8*3 rs10509681, CYP2C9*2 rs1799853, CYP2C9 rs2153628, and CYP2C9*3 rs1057910. Allele frequencies were compared between responders and non-responders, and non-genetic predictors were assessed using logistic regression. A total of 146 infants were identified. Of these, 86 were enrolled. Genetic analysis showed that the heterozygote genotype (TC) for the CYP2C8 gene was the most common (45%), while wild-type alleles were predominant for CYP2C9 variants. No significant differences in allele frequencies were found between responders and non-responders to the treatment (p > 0.05). In a secondary analysis, the need for multiple surfactant doses independently predicted poor response (aOR 0.244, 95% CI 0.086–0.693, p = 0.008), while extremely low birth weight showed a borderline association (aOR 0.281, 95% CI 0.062–1.268, p = 0.099). Carriers of CYP2C8*3 rs10509681, CYP2C9*2 rs1799853, CYP2C9 rs2153628, and CYP2C9*3 rs1057910 were not associated with variations in response to NSAIDs.